Division of Nephrology, State University of New York at Downstate, 450 Clarkson Avenue, Box 52, Brooklyn, New York, 11203, USA.
Division of Nephrology, Hofstra Northwell School of Medicine, Manhasset, USA.
BMC Nephrol. 2018 Jun 22;19(1):147. doi: 10.1186/s12882-018-0943-0.
There are no guidelines for transitioning patients from chronic kidney disease stage 5 to hemodialysis. We conducted this study to determine if there are uniform patterns in how nephrologists transition patients to dialysis.
We designed an electronic survey with 39 questions and sent it to a database of practicing nephrologists at the National Kidney Foundation. Factors that were important for transitioning a patient to hemodialysis were evaluated, including medication changes on dialysis initiation, dry weight and dialysis prescription.
160 US Nephrologists replied to the survey; 18% (29/160) of the responses were completed via social media sites. Prior to dialysis, 74% (118/160), prescribed furosemide and 67% (107/160) used furosemide with metolazone. Once dialysis started, only 46% (74/160) of the responders continued patients on diuretics daily. Hypertension medications prescribed in dialysis were calcium channel blockers 69% (112/160), beta blockers 36% (58/160), angiotensin converting enzyme inhibitor 32% (53/160), angiotensin receptor blocker 29% (46/160) and diuretics 25% (42/160). Once dialysis started, 68% (109/160) routinely changed medications. Most, 67% (107/160) ordered patients to avoid anti-hypertensive medications on dialysis days to allow for ultrafiltration. Dry weight was determined in the first week by 29% (46/160) and in the first month by 53% (85/160). Most, 59% (94/160) felt that multiple causes lead to hypertension. Most nephrologists would prescribe small dialyzers and a shorter period of time for the first dialysis session.
The transition period to chronic hemodialysis has variations in practice patterns and may benefit from further studies to optimize clinical practice.
目前尚无关于慢性肾脏病 5 期患者向血液透析过渡的指南。我们进行这项研究是为了确定肾内科医生在将患者过渡到透析时是否存在统一的模式。
我们设计了一个包含 39 个问题的电子调查,并将其发送给美国肾脏病基金会的肾内科医生数据库。评估了将患者过渡到血液透析的重要因素,包括透析开始时的药物变化、干体重和透析处方。
160 名美国肾内科医生回复了这项调查;29/160(18%)的回复是通过社交媒体网站完成的。在开始透析之前,74%(118/160)的医生开呋塞米,67%(107/160)的医生用呋塞米和甲氯噻嗪。一旦开始透析,只有 46%(74/160)的应答者每天继续为患者开利尿剂。在透析中开的高血压药物是钙通道阻滞剂 69%(112/160)、β受体阻滞剂 36%(58/160)、血管紧张素转换酶抑制剂 32%(53/160)、血管紧张素受体阻滞剂 29%(46/160)和利尿剂 25%(42/160)。一旦开始透析,68%(109/160)的医生会定期改变药物。大多数医生(107/160)会让患者在透析日避免使用抗高血压药物,以允许超滤。干体重在第一周由 29%(46/160)确定,在第一个月由 53%(85/160)确定。大多数医生(59%,94/160)认为多种原因导致高血压。大多数肾内科医生会为首次透析开小透析器和较短的透析时间。
向慢性血液透析过渡期间,实践模式存在差异,可能需要进一步研究来优化临床实践。